Full Press Release Details
Update on Regulatory Review of Aducanumab in the European Union.
BIIB
Update on Regulatory Review of Aducanumab in the European Union
Key Takeaway: Update on Regulatory Review of Aducanumab in the European Union
Price reaction · baseline $261.55 (2021-11-16 close) · hit after-hours · clean, no other BIIB news in the window
day 0 close
-1.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis